Percheron Therapeutics Limited
PERCF
$0.0025
-$0.0165-86.84%
OTC PK
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, February 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 25 and 29 (est)
Price History
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 3 9827 8999
Address
L30, Collins Place
Melbourne, VIC 3000
Melbourne, VIC 3000
Country
Year Founded
Business Description
Sector
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of...
more